SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

  Back

15 Apr 2024 5:45 p.m. 6:45 p.m.

WCN24-AB-847, Poster Board= MON-296

Jonathan Barratt Poster Presenter